New Stroke Therapy Data Will Debut in October
Researchers are set to present findings on a potential treatment for acute intracerebral hemorrhage.
Updated on Sept. 24, 2026 in Stroke
Live Poll
Should development of novel treatments for currently untreatable medical conditions like stroke be prioritized by industry?
Final results from the Phase 2a BIRCH trial, which investigated an experimental treatment for acute intracerebral hemorrhage, will be presented on October 21, 2026, at the World Stroke Congress in Seoul. The study tracked functional outcomes for 23 patients over 360 days.
Why it matters
Currently, there are no approved therapies for acute intracerebral hemorrhage, making the development of effective interventions a significant priority in stroke care. This trial represents an effort to identify a treatment option for a condition that lacks a standard medical remedy.
This proof-of-concept study enrolled 23 patients with first-ever spontaneous intracerebral hemorrhage ranging from 5 to 60 mL. Investigators utilized a 3:1 randomization ratio to compare the experimental infusion against standard of care, with outcomes tracked through Day 360.
The players
Bioxodes
A pharmaceutical company based in Gosselies, Belgium, focused on developing therapies for acute brain injuries.
World Stroke Congress
An international medical assembly in Seoul that facilitates the dissemination of research and clinical findings related to stroke treatment.
The details
The experimental drug, BIOX-101, is administered as a 48-hour intravenous infusion. To be eligible for the trial, patients had to begin the infusion within 24 hours of symptom onset. The study aim was to evaluate the drug's impact on patient recovery following a spontaneous bleed in the brain.
Timeline
Topline trial data were reported in May 2026.
The presentation of the final dataset is scheduled for October 21, 2026.
The World Stroke Congress will take place from October 21-23, 2026.
Health Landscape
The announcement of these results marks a progression in the BIRCH trial clinical program, which seeks to establish the first pharmacologic intervention for spontaneous hemorrhagic stroke. The development follows an ongoing industry shift toward identifying targeted therapies for intracranial bleeding.
Because no current FDA-approved drug exists for acute intracerebral hemorrhage, patients and families should monitor reports for potential future clinical trial opportunities. Any questions regarding new treatment approaches for stroke should be directed to a neurologist or specialized stroke care team.
The takeaway
The lack of approved treatments for hemorrhagic stroke remains a major gap in acute care medicine. Patients and caregivers should remain informed about clinical trial statuses through official medical congress announcements and consult their physician regarding ongoing research developments.
What happens next
Bioxodes is currently preparing to launch the Phase 2b BIRCH 2 trial, which aims to enroll approximately 200 patients to further evaluate the treatment.
Further reading
Learn more about the latest research and clinical developments in our Stroke section.
Live Poll
Should development of novel treatments for currently untreatable medical conditions like stroke be prioritized by industry?
